International nonproprietary name: difference between revisions

Diff·revision 10 → 11·21:25, 18 Feb 2025

Difference between revision 10 and revision 11 of International nonproprietary name. 7 lines changed; the page grew by 356 bytes.

Revision 10 — 10:42, 3 Feb 2025 A1c_Alder (talk) state plainly that the research-use-only form is not approved for human use 2,789 bytes +34	Revision 11 — 21:25, 18 Feb 2025 Chromatokid (talk) expand §Relationship to trade and chemical names 3,145 bytes +356
33	Trade names are trademarks, differ between jurisdictions, and are chosen for marketing rather than for information. A trade name conveys nothing about pharmacological class by design, since a trademark resembling an INN stem would be refused.	33	Trade names are trademarks, differ between jurisdictions, and are chosen for marketing rather than for information. A trade name conveys nothing about pharmacological class by design, since a trademark resembling an INN stem would be refused.
34		34
+		35	Development codes — LY3437943, BI 456906 — precede the INN and appear in the early literature. A compound may be discussed under a code, then an INN, then a trade name, and secondary sources do not always connect them. See [[Retatrutide]] and [[Survodutide]].{{r\|who_inn}}
+		36
35	== References ==	37	== References ==
36	{{reflist}}	38	{{reflist}}
37	<ref name="who_inn">World Health Organization, ''Guidance on the Use of International Nonproprietary Names (INNs) for Pharmaceutical Substances'' and the published INN stem list.</ref>	39	<ref name="who_inn">World Health Organization, ''Guidance on the Use of International Nonproprietary Names (INNs) for Pharmaceutical Substances'' and the published INN stem list.</ref>
+		40
+		41	== See also ==
+		42	* [[Semaglutide]]
+		43	* [[Tirzepatide]]
+		44	* [[Counterfeit peptide]]
38		45
39	{{DEFAULTSORT:International nonproprietary name}}	46	{{DEFAULTSORT:International nonproprietary name}}